Trying to Calculate the Economic Value of Dasatinib or Nilotinib for Imatinib-Resistant CML

Trying to Calculate the Economic Value of Dasatinib or Nilotinib for Imatinib-Resistant CML Published Online: Thursday, March 28, 2013 Although it is now standard practice to utilize the second-generation tyrosine-kinase inhibitors dasatinib or nilotinib in patients whose chronic myeloid leukemia (CML) has recurred while taking imatinib treatment, published support for the economic value of this approach is lacking. Investigators from the University of Exeter, United Kingdom, conducted a review of the literature and produced an economic model to help fill this information gap.